Arcturus Therapeutics Holdings (ARCT) Income from Continuing Operations (2018 - 2026)
Arcturus Therapeutics Holdings (ARCT) reported Income from Continuing Operations of 28931000.0 for Q1 2026, down 105.53% on a YoY basis from 522763486.52 in Q1 2025, and up 0.51% quarter-over-quarter from 29079000.0 in Q4 2025.
Arcturus Therapeutics Holdings (ARCT) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings has reported Income from Continuing Operations for 9 years, with the latest figure at 28931000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 105.53% year-over-year to 28931000.0; the trailing twelve-month figure through Mar 2026 stood at 80638000.0 (down 18.24% YoY), and the FY2025 full-year result was 65783000.0, up 18.73% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 28931000.0, up from 29079000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 118642000.0 in Q4 2022, with the low at 52550000.0 in Q2 2023.
- Historically, Income from Continuing Operations has averaged 11463058.82 across 5 years, with a median of 17216000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations soared 415.16% — and 2024, when it tumbled 156.3%.
- Arcturus Therapeutics Holdings' Income from Continuing Operations stood at 118642000.0 in 2022, then slumped by 109.87% to 11707000.0 in 2023, then sank by 156.3% to 30005000.0 in 2024, then rose by 3.09% to 29079000.0 in 2025, then gained by 0.51% to 28931000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 28931000.0 (Q1 2026), 29079000.0 (Q4 2025), and 13448000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Arcturus Therapeutics Holdings | 217.14 Mn | 5.76 Mn | - | -28.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.93 Mn |
| Dec 31, 2025 | -29.08 Mn |
| Sep 30, 2025 | -13.45 Mn |
| Jun 30, 2025 | -9.18 Mn |
| Mar 31, 2025 | -14.08 Mn |
| Dec 31, 2024 | -30.01 Mn |
| Sep 30, 2024 | -6.90 Mn |
| Jun 30, 2024 | -17.22 Mn |
| Mar 31, 2024 | -26.85 Mn |
| Dec 31, 2023 | -11.71 Mn |
| Sep 30, 2023 | -16.23 Mn |
| Jun 30, 2023 | -52.55 Mn |
| Mar 31, 2023 | 50.76 Mn |
| Dec 31, 2022 | 118.64 Mn |
| Sep 30, 2022 | -35.27 Mn |
| Jun 30, 2022 | -21.56 Mn |
| Mar 31, 2022 | -51.27 Mn |
| Dec 31, 2021 | -37.65 Mn |
| Sep 30, 2021 | -53.82 Mn |
| Jun 30, 2021 | -53.72 Mn |